ASP5834 + panitumumab

ASP5834 + panitumumab is an investigational **combination therapy** currently in phase 1 trials for the treatment of advanced solid tumors with specific KRAS mutations, focusing on colorectal cancer. **ASP5834** is a first-in-human, intravenous small-molecule pan-KRAS degrader developed by Astellas and designed to degrade multiple mutant KRAS proteins implicated in various cancers[6][1]. **Panitumumab** is a fully human monoclonal antibody that targets and inhibits the epidermal growth factor receptor (EGFR) and is approved for metastatic colorectal cancer. The combination aims to synergistically inhibit the growth of KRAS-mutant tumors by dual targeting of the KRAS pathway (by degradation) and EGFR signaling[1][3].